Filing Details
- Accession Number:
- 0001562180-24-004026
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-14 16:05:25
- Reporting Period:
- 2024-05-13
- Accepted Time:
- 2024-05-14 16:05:25
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1517022 | Akebia Therapeutics Inc. | AKBA | Pharmaceutical Preparations (2834) | 208756903 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1602396 | R. Nicole Hadas | C/O Akebia Therapeutics, Inc. 245 First Street Cambridge MA 02142 | Svp, Chief Legal Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-05-13 | 12,016 | $1.26 | 651,243 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023.
- This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.